Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 July 2021Website:
http://www.hcwbiologics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 01 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
What type of business is HCW Biologics?
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
What sector is HCW Biologics in?
HCW Biologics is in the Healthcare sector
What industry is HCW Biologics in?
HCW Biologics is in the Biotechnology industry
What country is HCW Biologics from?
HCW Biologics is headquartered in United States
When did HCW Biologics go public?
HCW Biologics initial public offering (IPO) was on 20 July 2021
What is HCW Biologics website?
https://www.hcwbiologics.com
Is HCW Biologics in the S&P 500?
No, HCW Biologics is not included in the S&P 500 index
Is HCW Biologics in the NASDAQ 100?
No, HCW Biologics is not included in the NASDAQ 100 index
Is HCW Biologics in the Dow Jones?
No, HCW Biologics is not included in the Dow Jones index
When does HCW Biologics report earnings?
The next expected earnings date for HCW Biologics is 09 August 2024